Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.78 AUD | 0.00% | -0.28% | -7.53% |
Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 23.83M | Sales 2025 * | 60.9M 38.8M | Capitalization | 168M 107M |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.27M | Net income 2025 * | 11M 7.01M | EV / Sales 2024 * | 4.48 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.75 x |
P/E ratio 2024 * |
-70
x | P/E ratio 2025 * |
14.3
x | Employees | 87 |
Yield 2024 * |
0.57% | Yield 2025 * |
3.49% | Free-Float | 45.15% |
1 week | -0.28% | ||
Current month | -0.84% | ||
3 months | -5.57% | ||
6 months | -21.93% | ||
Current year | -7.53% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
Mathew Farag
COO | Chief Operating Officer | - | 16-12-31 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 19-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 21-08-09 |
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
David Heaney
CHM | Chairman | 79 | 06-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1.78 | 0.00% | 5 000 |
24-04-18 | 1.78 | -1.11% | 15,980 |
24-04-17 | 1.8 | +0.84% | 2,000 |
24-04-16 | 1.785 | 0.00% | 3,780 |
24-04-15 | 1.785 | 0.00% | 502 |
Delayed Quote Australian S.E., April 18, 2024 at 08:02 pm EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.53% | 109M | |
+2.02% | 209B | |
+2.17% | 177B | |
+10.45% | 133B | |
+16.62% | 99.89B | |
-2.70% | 61.83B | |
+13.38% | 52.51B | |
-6.33% | 45.54B | |
-4.74% | 39.43B | |
+9.89% | 38.87B |
- Stock Market
- Equities
- CYC Stock